vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Loar Holdings Inc. (LOAR). Click either name above to swap in a different company.
Loar Holdings Inc. is the larger business by last-quarter revenue ($131.8M vs $86.8M, roughly 1.5× IOVANCE BIOTHERAPEUTICS, INC.). On growth, Loar Holdings Inc. posted the faster year-over-year revenue change (19.3% vs 17.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 19.8%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
IOVA vs LOAR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $131.8M |
| Net Profit | — | $12.5M |
| Gross Margin | 67.4% | 52.1% |
| Operating Margin | -84.7% | 18.0% |
| Net Margin | — | 9.5% |
| Revenue YoY | 17.7% | 19.3% |
| Net Profit YoY | — | 239.5% |
| EPS (diluted) | — | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $131.8M | ||
| Q3 25 | $67.5M | $126.8M | ||
| Q2 25 | $60.0M | $123.1M | ||
| Q1 25 | $49.3M | $114.7M | ||
| Q4 24 | $73.7M | $110.4M | ||
| Q3 24 | $58.6M | $103.5M | ||
| Q2 24 | $31.1M | $97.0M | ||
| Q1 24 | $715.0K | $91.8M |
| Q4 25 | — | $12.5M | ||
| Q3 25 | $-91.3M | $27.6M | ||
| Q2 25 | $-111.7M | $16.7M | ||
| Q1 25 | $-116.2M | $15.3M | ||
| Q4 24 | — | $3.7M | ||
| Q3 24 | $-83.5M | $8.7M | ||
| Q2 24 | $-97.1M | $7.6M | ||
| Q1 24 | $-113.0M | $2.2M |
| Q4 25 | 67.4% | 52.1% | ||
| Q3 25 | 43.0% | 52.7% | ||
| Q2 25 | 5.5% | 53.8% | ||
| Q1 25 | -0.8% | 52.1% | ||
| Q4 24 | 68.7% | 48.9% | ||
| Q3 24 | 46.2% | 51.1% | ||
| Q2 24 | -0.8% | 49.0% | ||
| Q1 24 | — | 48.4% |
| Q4 25 | -84.7% | 18.0% | ||
| Q3 25 | -140.7% | 22.9% | ||
| Q2 25 | -189.8% | 22.2% | ||
| Q1 25 | -245.8% | 22.8% | ||
| Q4 24 | -117.5% | 19.2% | ||
| Q3 24 | -152.1% | 22.1% | ||
| Q2 24 | -327.6% | 22.9% | ||
| Q1 24 | -16464.6% | 23.3% |
| Q4 25 | — | 9.5% | ||
| Q3 25 | -135.3% | 21.8% | ||
| Q2 25 | -186.2% | 13.6% | ||
| Q1 25 | -235.5% | 13.4% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -142.7% | 8.4% | ||
| Q2 24 | -312.2% | 7.9% | ||
| Q1 24 | -15800.8% | 2.4% |
| Q4 25 | — | $0.13 | ||
| Q3 25 | — | $0.29 | ||
| Q2 25 | $-0.33 | $0.17 | ||
| Q1 25 | $-0.36 | $0.16 | ||
| Q4 24 | $-0.24 | $-11023.48 | ||
| Q3 24 | $-0.28 | $0.09 | ||
| Q2 24 | $-0.34 | $0.09 | ||
| Q1 24 | $-0.42 | $11023.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $84.8M |
| Total DebtLower is stronger | — | $715.7M |
| Stockholders' EquityBook value | $698.6M | $1.2B |
| Total Assets | $913.2M | $2.0B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $84.8M | ||
| Q3 25 | $300.8M | $99.0M | ||
| Q2 25 | $301.2M | $103.3M | ||
| Q1 25 | $359.7M | $80.5M | ||
| Q4 24 | $323.8M | $54.1M | ||
| Q3 24 | $397.5M | $55.2M | ||
| Q2 24 | $412.5M | $73.2M | ||
| Q1 24 | $356.2M | $28.2M |
| Q4 25 | — | $715.7M | ||
| Q3 25 | — | $279.4M | ||
| Q2 25 | — | $277.7M | ||
| Q1 25 | — | $277.5M | ||
| Q4 24 | — | $277.3M | ||
| Q3 24 | — | $602.1M | ||
| Q2 24 | — | $250.7M | ||
| Q1 24 | — | $534.2M |
| Q4 25 | $698.6M | $1.2B | ||
| Q3 25 | $702.3M | $1.2B | ||
| Q2 25 | $698.5M | $1.1B | ||
| Q1 25 | $767.9M | $1.1B | ||
| Q4 24 | $710.4M | $1.1B | ||
| Q3 24 | $773.5M | $769.8M | ||
| Q2 24 | $768.5M | $758.4M | ||
| Q1 24 | $680.0M | $420.6M |
| Q4 25 | $913.2M | $2.0B | ||
| Q3 25 | $904.9M | $1.5B | ||
| Q2 25 | $907.4M | $1.5B | ||
| Q1 25 | $966.7M | $1.5B | ||
| Q4 24 | $910.4M | $1.5B | ||
| Q3 24 | $991.1M | $1.5B | ||
| Q2 24 | $964.3M | $1.1B | ||
| Q1 24 | $869.8M | $1.1B |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | 0.78× | ||
| Q2 24 | — | 0.33× | ||
| Q1 24 | — | 1.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $30.4M |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | 2.43× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $30.4M | ||
| Q3 25 | $-78.7M | $29.7M | ||
| Q2 25 | $-67.4M | $23.8M | ||
| Q1 25 | $-103.7M | $28.4M | ||
| Q4 24 | $-73.3M | $20.7M | ||
| Q3 24 | $-59.0M | $16.3M | ||
| Q2 24 | $-98.4M | $7.1M | ||
| Q1 24 | $-122.3M | $10.8M |
| Q4 25 | $-61.9M | — | ||
| Q3 25 | $-89.5M | — | ||
| Q2 25 | $-74.9M | — | ||
| Q1 25 | $-109.9M | — | ||
| Q4 24 | $-77.5M | — | ||
| Q3 24 | $-61.3M | — | ||
| Q2 24 | $-98.9M | — | ||
| Q1 24 | $-126.5M | — |
| Q4 25 | -71.3% | — | ||
| Q3 25 | -132.7% | — | ||
| Q2 25 | -124.9% | — | ||
| Q1 25 | -222.8% | — | ||
| Q4 24 | -105.1% | — | ||
| Q3 24 | -104.6% | — | ||
| Q2 24 | -317.9% | — | ||
| Q1 24 | -17685.3% | — |
| Q4 25 | 10.7% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | 12.6% | — | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 583.4% | — |
| Q4 25 | — | 2.43× | ||
| Q3 25 | — | 1.08× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 1.85× | ||
| Q4 24 | — | 5.62× | ||
| Q3 24 | — | 1.89× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | — | 4.81× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
